Antares Pharma (ATRS) Osake Kurssi

Antares Pharma Inc is primarily active in the pharmaceutical industry.

The main competitors of Antares Pharma Inc in the market are pharmaceutical companies such as Eli Lilly and Company, Novartis AG, Pfizer Inc, Johnson & Johnson, and Amgen Inc.

Antares Pharma Inc. is a biopharmaceutical company specializing in the development and commercialization of self-administered parenteral pharmaceutical products. Founded in 1979, Antares Pharma has a rich history of innovation and scientific expertise. The company focuses on advanced drug delivery technologies, including its proprietary needle-free injection system, to improve patient convenience and adherence. With a strong commitment to research and development, Antares Pharma has successfully brought several products to market and licenses its technologies to pharmaceutical partners worldwide. The company's dedication to improving therapeutic outcomes has earned it a reputable position in the pharmaceutical industry.

Antares Pharma Inc has achieved significant milestones throughout its years of operation. Notably, the company received FDA approval for its flagship product, the Otrexup™ self-injection device, a breakthrough treatment for patients with rheumatoid arthritis and psoriasis. Antares also secured licensing agreements with leading pharmaceutical companies, including Teva and AMAG, further extending its market reach. In addition, the company successfully launched the Makena® subcutaneous auto injector, enhancing patient convenience for a hormone therapy drug used in high-risk pregnancies. Antares Pharma Inc continues to innovate, pursue strategic collaborations, and make remarkable progress in delivering advanced pharmaceutical solutions.

Antares Pharma Inc is primarily present in the United States.

Antares Pharma Inc represents a set of key values and a strong corporate philosophy. With a focus on innovation, Antares Pharma Inc strives to develop and commercialize pharmaceutical products that improve patients' lives. The company places great importance on quality, aiming to deliver safe and effective treatments. Antares Pharma Inc is committed to fostering a culture of integrity and ethical business practices, ensuring transparency and accountability in all its operations. By prioritizing customer needs and collaboration, Antares Pharma Inc aims to drive shareholder value and establish itself as a leader in the pharmaceutical industry.

12 analyytikkoa arvioi tällä hetkellä Antares Pharma-osaketta: 6 suosittaa ostoa, 6 pitoa ja 0 myyntiä.

Antares Pharma Analyytikkojen kursstavoitteet 2026

Antares Pharma-osake (ATRS) on listattuna 2 pörssissä, muun muassa: NASDAQ (ATRS), SIX (Zürich) (MJC.SW).

Antares Pharma Inc is a company that specializes in the development, manufacturing, and marketing of medications, particularly injection solutions. The company has three main business areas: 1. Marketing and manufacturing of medications: Antares Pharma produces and markets primarily injection solutions for various applications. The company has several leading products, including the legal opioid Vergentanib, hormone injections for women, disposable insulin pens, and more. 2. Research and development: Antares Pharma is dedicated to advancing the development of new medications and injection systems. The company heavily invests in research and development to create innovative products that meet the needs of patients. 3. Licensing and partnerships: Antares Pharma also collaborates with other pharmaceutical companies to distribute its products worldwide. The company has partnerships with companies such as Teva, Ferring, and Pfizer to globally market its products. The company offers several leading products: 1. Vergentanib: Vergentanib is a legal opioid for pain relief. The medication is administered through a pre-filled syringe pen manufactured by Antares Pharma. Vergentanib is a widely approved medication available in many countries worldwide. 2. OTREXUP: OTREXUP is a disposable insulin pen for the treatment of diabetes. The insulin pen is made from a special material that reduces the risk of overdosing. 3. QuickShot: QuickShot is a disposable injection system for hormone injections for women. The system is convenient and easy to use, and is utilized by many women around the world. Antares Pharma's business model is based on the development and marketing of injection products for various applications. The company invests in research and development to create innovative products that meet the needs of patients. Antares Pharma also collaborates with partners to market its products worldwide. The company has a strong presence in the market and strives to continue developing and distributing top-quality products to assist patients.

Liikevaihtoa ei voida laskea Antares Pharma:lle tällä hetkellä.

Voittoa ei voida laskea Antares Pharma:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Antares Pharma:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Antares Pharma:lle tällä hetkellä.

Antares Pharma:n Eulpool-laatuscore on 8/10.

Antares Pharma:n ISIN on US0366421065. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Antares Pharma:n WKN on 903128. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Antares Pharma:n ticker on ATRS. Tämä pörssinoteeraus käytetään Antares Pharma-osakkeiden kauppaan pörssissä.